HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Potassium Iodide Education Efforts To Highlight Dosage, Timing Of Use

This article was originally published in The Tan Sheet

Executive Summary

Public education efforts on use of potassium iodide (KI) during radiation emergencies will focus, in part, on when and how much of the OTC drug should be taken by residents living near nuclear power plants

You may also be interested in...



Potassium Iodide Stockpiling Guidelines Called For In Bioterrorism Bill

Within a year of enacting bioterrorism legislation, the Bush Administration will consult with federal, state and local agencies to establish guidelines for the stockpiling of potassium iodide (KI) tablets

Bioterrorism Preparedness Addressed On Capitol Hill, At FDA

Any facility that manufactures, processes, packs or holds food for consumption in the U.S. would have to register with HHS within 180 days of the enactment of a bioterrorism bill passed by the House Dec. 12

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS130489

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel